Timothy Miller, MD, PhD
Credit: Washington University Photographic Services
Tau Consortium Researchers Advance a Promising New Treatment for PSP, CTE and Alzheimer’s Disease
The Tau Consortium wishes to congratulate Dr. Tim Miller and his colleagues on the recent publication of an exciting new study showing that antisense oligonucleotides (ASOs) can reverse tau pathology and extend survival in mice. With these results in hand, human clinical trials could begin by the end of the year.
"When our father was diagnosed with progressive supranuclear palsy, there were alarmingly few treatment options. Now, there are glimmers of hope. Our hearts go out to the people who are facing these terrible diseases, and we hope this news will inspire them to keep fighting. We are immensely grateful to all of the researchers who have dedicated their time and talent to this research."
—Matthew Rainwater, Trustee, Rainwater Charitable Foundation
Dr. Miller’s peer-reviewed article appears in the January 25th issue of Science Translational Medicine.
- View the scientific abstract
- Read a plain English description of the study results, including additional commentary from Dr. Miller
- Read the Rainwater Charitable Foundation’s press release about the implications of this study
For media inquiries, please contact Tau Consortium Program Director Patrick Brannelly at 650.743.7141 or email@example.com.